Topical formulation containing exosomes for treatment of canine atopic dermatitis

• Grant number: 24/10500-5
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: April 01, 2025
• End date: March 31, 2026
• Field of knowledge: Health Sciences - Medicine
• Agreement: SEBRAE-SP
• Principal Investigator: Carolina Caliári Oliveira
• Grantee: Carolina Caliári Oliveira
• Company: In Situ Terapia Celular Ltda
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• Associated researchers: Adriana Oliveira Manfiolli ; Ana Augusta Pagnano Derussi
• Associated scholarship(s): 25/07890-9 - Isolation and Characterization of Mesenchymal Cell-Derived Exosomes for Incorporation into a Topical Formulation for the Treatment of Canine Atopic Dermatitis, BP.TT

Abstract

The proposed technological solution involves the development of a product containing exosomes derived from mesenchymal stromal cells (MSCs) formulated in a topical spray to facilitate application and penetration into the skin of dogs with atopic dermatitis. This solution aims to address the specific challenges associated with CAD in an innovative and effective manner. MSC exosomes have potent immunomodulatory and anti-inflammatory properties, making them promising candidates for the treatment of chronic inflammatory conditions such as CAD. They contain a complex cargo of bioactive molecules (proteins, lipids, and microRNAs) that reduce inflammation, modulate the immune response, and promote skin healing and tissue regeneration. Additionally, In Situ, the company behind this proposal, previously developed a Biogel containing exosomes and demonstrated the product's safety in in vitro and preclinical studies, as well as its efficacy in an experimental wound model in mice. In this project, we propose the adaptation of the Biogel product into a spray for better applicability in the treatment of CAD. (AU)